Clinical Research Center, School of Optometry, University of California, Berkeley
Berkeley, California, 94720-2020, United States
NCT Number: NCT05705518
Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. In this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Berkeley, California, 94720-2020, United States
This is a prospective, double-masked, randomized, controlled, parallel-group trial designed to compare the impact of Systane Complete PF lipid-based artificial tears (the Treatment solution under study) on tear lipid layer thickness compared with a non-lipid Control solution, Refresh Relieva PF. Secondarily, the study will compare changes in tear lipid layer thickness, lipid layer uniformity, tear film thinning dynamics, and symptoms between the Treatment solution, the non-lipid Control solution, and 2 other available lipid-based solutions (Active Comparators: Refresh Optive Mega-3 PF and CVS Health Lubricant Eye Drop (PG 0.6%)). The study will include 4 clinic visits, and require 1 week of single-masked run-in with Systane Ultra PF (an over-the-counter non-lipid-based solution) followed by 3 months of study treatment dosing. All subjects will complete a screening interview, then an in-clinic baseline ocular health examination and study eligibility determination followed by dispensing of the Control solution to all subjects for 1 week of run-in. After that week, subjects will be randomized to 1 of the 4 artificial tear solutions and have an in-clinic ocular examination and dispense of the assigned solution to use for 3 months. An in-clinic follow-up examination is completed after 1 month of study solution use, followed by a phone interview at 2 months, and a final in-clinic examination at 3 months post-dispensing.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
Time frame: Lipid Layer Thickness measured once at post-run-in baseline and once at 3mo follow-up visit
Change in Tear Lipid Layer Thickness (3mo follow-up - post-run-in baseline)
Time frame: Lipid Layer Uniformity measured once at post-run-in baseline and once at 3mo follow-up visit
Change (3mo follow-up - post-run-in baseline) in Tear Lipid Layer Thickness Coefficient of Variation (CV). The CV is calculated as the standard deviation divided by the mean lipid layer thickness. A greater value of the CV indicates more variability in lipid layer thickness, a smaller value of the CV indicates a more uniformly thick lipid layer.
Time frame: Tear Film Thinning Rate measured once at post-run-in baseline and once at 3mo follow-up visit
Change in Tear Film Thinning rate (3mo follow-up - post-run-in baseline)
Time frame: OSDI questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit
Change (3mo follow-up - post-run-in baseline) in Ocular Surface Disease Index (OSDI) score. The OSDI questionnaire score ranges from 0-100, with higher scores indicating more severe symptoms of Dry Eye Disease.
Time frame: SANDE questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit
Change in Symptom Assessment questionnaire iN Dry Eye (SANDE) score (3mo follow-up - post-run-in baseline)
Time frame: DEQ-5 questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit
Change in 5-Item Dry Eye Questionnaire (DEQ-5) score (3mo follow-up - post-run-in baseline)
University of California, Berkeley
Other
Effects Of Artificial Tears on Tear Lipid Films and Tear Film Dynamics In Vivo
Acronym: AlconAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07089511
Dry Eye, Dry Eye Syndromes
Milan, Italy
View Trial DetailsNCT06346340
Dry Eye, Dry Eye Syndromes
Laguna Hills, California, United States
View Trial DetailsNCT07675460
Acne Cystic, Choroidal Thickness
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial Details